Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDMO Avid Bioservices	$12.50 +0.1%	$12.50	$8.74 ▼ $12.51	$799.18M	1.39	1.45 million shs	3.07 million shs
CRNX Crinetics Pharmaceuticals	$26.85 -3.7%	$30.58	$24.10 ▼ $62.53	$2.51B	0.33	861,489 shs	2.00 million shs
HCM HUTCHMED	$15.00 -8.0%	$16.40	$11.51 ▼ $21.50	$2.62B	0.55	38,920 shs	129,176 shs
KYMR Kymera Therapeutics	$40.62 -0.6%	$45.11	$19.44 ▼ $53.27	$2.65B	2.18	524,846 shs	840,550 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDMO Avid Bioservices	0.00%	0.00%	0.00%	0.00%	+23.22%
CRNX Crinetics Pharmaceuticals	0.00%	-3.56%	-16.07%	-12.48%	-44.41%
HCM HUTCHMED	0.00%	-13.14%	-6.07%	+5.19%	-23.59%
KYMR Kymera Therapeutics	0.00%	-5.45%	-10.15%	+35.08%	+0.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CDMO Avid Bioservices	0.8602 of 5 stars	1.0	0.0	4.5	0.0	1.7	0.6
CRNX Crinetics Pharmaceuticals	3.3631 of 5 stars	3.4	0.0	3.7	2.3	2.5	0.0
HCM HUTCHMED	3.1244 of 5 stars	3.3	4.0	0.0	2.9	0.0	1.9
KYMR Kymera Therapeutics	3.3468 of 5 stars	4.6	3.0	0.0	2.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDMO Avid Bioservices	2.00	Hold	$12.25	-1.96% Downside
CRNX Crinetics Pharmaceuticals	2.78	Moderate Buy	$69.00	156.98% Upside
HCM HUTCHMED	2.50	Moderate Buy	$28.00	86.67% Upside
KYMR Kymera Therapeutics	3.10	Buy	$59.11	45.52% Upside

Current Analyst Ratings Breakdown

Latest CDMO, HCM, KYMR, and CRNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$60.00
7/22/2025	HCM HUTCHMED	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $28.00
7/15/2025	KYMR Kymera Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/10/2025	CRNX Crinetics Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$36.00
7/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$70.00
6/27/2025	CRNX Crinetics Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/27/2025	KYMR Kymera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$56.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$59.00
6/26/2025	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$57.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $60.00
6/25/2025	KYMR Kymera Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$64.00

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDMO Avid Bioservices	$139.91M	5.71	$0.15 per share	80.92	$3.02 per share	4.14
CRNX Crinetics Pharmaceuticals	$1.04M	2,417.27	N/A	N/A	$14.29 per share	1.88
HCM HUTCHMED	$630.20M	4.15	$0.29 per share	52.22	$4.43 per share	3.39
KYMR Kymera Therapeutics	$47.07M	56.20	N/A	N/A	$12.90 per share	3.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDMO Avid Bioservices	-$140.75M	-$2.39	N/A	N/A	N/A	-101.07%	-33.18%	-8.45%	9/8/2025 (Estimated)
CRNX Crinetics Pharmaceuticals	-$298.41M	-$3.82	N/A	N/A	N/A	N/A	-32.52%	-29.72%	N/A
HCM HUTCHMED	$37.73M	N/A	0.00	10.27	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	N/A	-409.07%	-30.11%	-25.65%	8/11/2025 (Estimated)

Latest CDMO, HCM, KYMR, and CRNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.84	N/A	N/A	N/A	$17.37 million	N/A
8/7/2025	Q2 2025	CRNX Crinetics Pharmaceuticals	-$1.13	-$1.23	-$0.10	-$1.23	$0.52 million	$1.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDMO Avid Bioservices	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDMO Avid Bioservices	3.58	1.30	0.92
CRNX Crinetics Pharmaceuticals	N/A	22.53	22.53
HCM HUTCHMED	0.08	2.83	2.70
KYMR Kymera Therapeutics	N/A	8.49	8.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDMO Avid Bioservices	97.16%
CRNX Crinetics Pharmaceuticals	98.51%
HCM HUTCHMED	8.82%
KYMR Kymera Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CDMO Avid Bioservices	3.05%
CRNX Crinetics Pharmaceuticals	4.60%
HCM HUTCHMED	3.60%
KYMR Kymera Therapeutics	16.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDMO Avid Bioservices	320	63.96 million	62.01 million	Optionable
CRNX Crinetics Pharmaceuticals	210	93.63 million	89.32 million	Optionable
HCM HUTCHMED	1,811	174.42 million	168.14 million	Not Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable

CDMO, HCM, KYMR, and CRNX Headlines

Recent News About These Companies

Stocks With Rising Relative Price Strength: Kymera Therapeutics

August 6, 2025 | msn.com

Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025

August 5, 2025 | finance.yahoo.com

TD Asset Management Inc Sells 26,468 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

August 3, 2025 | marketbeat.com

Victory Capital Management Inc. Cuts Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

August 3, 2025 | marketbeat.com

Equities Analysts Offer Predictions for KYMR Q2 Earnings

August 3, 2025 | americanbankingnews.com

Q2 Earnings Estimate for KYMR Issued By B. Riley

August 2, 2025 | marketbeat.com

B. Riley Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR)

July 31, 2025 | marketbeat.com

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

July 30, 2025 | zacks.com

Kymera Therapeutics (KYMR) to Release Quarterly Earnings on Wednesday

July 30, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Trims Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

July 30, 2025 | marketbeat.com

Neo Ivy Capital Management Invests $395,000 in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

July 27, 2025 | marketbeat.com

Jennison Associates LLC Sells 164,647 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

July 21, 2025 | marketbeat.com

Kymera Therapeutics (NASDAQ:KYMR) Upgraded at The Goldman Sachs Group

July 18, 2025 | marketbeat.com

Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?

July 18, 2025 | zacks.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Buy" from Analysts

July 17, 2025 | marketbeat.com

Kymera Therapeutics Inc (KYMR) - Investing.com

July 11, 2025 | investing.com

Kymera Therapeutics (KYMR) director group buys $13.9 million in stock

July 3, 2025 | investing.com

Tuesday’s Insider Activity: Major Buys and Sells Shake Up Markets

July 3, 2025 | investing.com

Insider Buying: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Buys 317,167 Shares of Stock

July 2, 2025 | insidertrades.com

Bros. Advisors Lp Baker Purchases 655,500 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock

July 1, 2025 | insidertrades.com

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

June 26, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDMO, HCM, KYMR, and CRNX Company Descriptions

Avid Bioservices NASDAQ:CDMO

Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.

Crinetics Pharmaceuticals NASDAQ:CRNX

$26.85 -1.03 (-3.69%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$26.85 0.00 (0.00%)

As of 08/8/2025 07:13 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

HUTCHMED NASDAQ:HCM

$15.00 -1.31 (-8.03%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$15.07 +0.07 (+0.47%)

As of 08/8/2025 07:41 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Kymera Therapeutics NASDAQ:KYMR

$40.62 -0.23 (-0.56%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$40.62 +0.01 (+0.01%)

As of 08/8/2025 04:14 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time